CA
BCRX icon

Clearstead Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Clearstead Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6K Buy
160
+101
+171% +$913 ﹤0.01% 2552
2026
Q1 		$566 Buy
59
+55
+1,375% +$427 ﹤0.01% 2108
2025
Q4 		$32 Buy
+4
New +$29 ﹤0.01% 2650
2025
Q3 		– Sell
-17
Closed -$153 – 3106
2025
Q2 		$153 Buy
+17
New +$158 ﹤0.01% 2581

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Clearstead Advisors's BCRX Position: Q2 2026 in Review

Clearstead Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 171% in Q2 2026, buying an estimated $913 and bringing the position to 160 shares worth $1.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2552.

Clearstead Advisors first reported a position in BCRX in Q2 2025 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Clearstead Advisors held 160 shares of BioCryst Pharmaceuticals worth $1.6K as of Q2 2026.
  • Clearstead Advisors bought 101 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $913.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2552 holding.
  • Clearstead Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.